According to Lugano response criteria, FDG-PET is mandatory to define metabolic response to frontline therapy and moreover it is important in the definition of non-responders or refractory disease patients. Refractory disease is reported in about 15% of patients, with some variations based on the choice of first line chemotherapy and particularly in advanced stages up to 40% eventually relapse within 3 years. Key Messagges: The aim of this review is to highlight a practical way to use FDG-PET in the subset of HL, with some notes of its use in first line patients, and particularly centred on relapsed or refractory setting with a final focus of the evaluation of response by FDG-PET in the new treatment era of immunocheckpoint inhibitors (CPI).
Keyphrases
- pet ct
- positron emission tomography
- pet imaging
- hodgkin lymphoma
- end stage renal disease
- computed tomography
- newly diagnosed
- ejection fraction
- chronic kidney disease
- acute myeloid leukemia
- acute lymphoblastic leukemia
- peritoneal dialysis
- prognostic factors
- stem cells
- mesenchymal stem cells
- multiple myeloma
- patient reported outcomes
- locally advanced
- rectal cancer
- cell therapy
- free survival